<p>加利福尼亚州福斯特城，2025 年 12 月 9 日（GLOBE NEWSWIRE）——Terns Pharmaceuticals, Inc.（“Terns” 或 “公司”）（纳斯达克：TERN），一家临床阶段的肿瘤学公司，今天宣布其增大规模的承销公开发行价格为每股 40.00 美元的 16,250,000 股普通股，未扣除承销折扣和佣金。此次发行的总收益预计为 6.5 亿美元，未扣除承销折扣和佣金及 Terns 需支付的其他发行费用，且不包括承销商购买额外股份的选择权。Terns 已授予承销商一个 30 天的选择权，以每股公开发行价格购买最多 2,437,500 股普通股，扣除承销折扣和佣金。此次发行预计将于 2025 年 12 月 11 日完成，需满足惯常的交割条件。所有证券均由 Terns 提供。</p>
<p>Jefferies、TD Cowen 和 Leerink Partners 担任此次发行的主要账簿管理人。Mizuho、Citizens Capital Markets 和 Oppenheimer &amp; Co.也担任此次发行的共同管理人。</p>
<p>Terns 计划将此次发行的净收益用于资助研究、临床试验、关键产品候选者的开发和生产，包括 TERN-701，准备 TERN-701 潜在未来商业发布的初步活动，以及用于营运资金和一般企业用途。</p>
<p>关于此次公开发行的证券，已于 2025 年 12 月 9 日向证券交易委员会（“SEC”）提交了 S-3 表格的注册声明（文件编号 333-292016），并于该日期自动生效。此次发行仅通过补充招股说明书和构成注册声明一部分的招股说明书进行。与此次发行相关的初步补充招股说明书和招股说明书已提交给 SEC，并可在 SEC 网站 www.sec.gov 上获取。与此次发行相关的最终补充招股说明书将提交给 SEC。初步补充招股说明书、最终补充招股说明书及与此次发行相关的招股说明书的副本在可用时可从 Jefferies LLC 索取，注意：股权承销招股说明书部门，地址：520 Madison Avenue, New York, NY 10022，电话：877-821-7388，或通过电子邮件联系 prospectus_department@jefferies.com，TD Securities (USA) LLC，c/o Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，或通过电子邮件联系 TDManualrequest@broadridge.com，或 Leerink Partners LLC，注意：承销部门，地址：53 State Street, 40th Floor, Boston, MA 02109，电话：1-800-808-7525 ex. 6105，或通过电子邮件联系 syndicate@leerink.com。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他管辖区内进行这些证券的出售，若在该州或其他管辖区内的证券法规定之前进行注册或资格审查，则该出售将是非法的。</p>
<p><strong>关于 Terns Pharmaceuticals</strong></p>
<p>Terns Pharmaceuticals 是一家临床阶段的肿瘤学公司，重新构想已知生物学，以提供高影响力的药物。我们的主导项目 TERN-701 是一种高度选择性的别构 BCR-ABL 抑制剂，具有潜在的最佳疾病特征，可能在慢性髓性白血病（CML）现有治疗的疗效、安全性和便利性方面显著改善。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含关于 Terns Pharmaceuticals, Inc.（“公司”、“我们” 或 “我们的”）的前瞻性声明，符合联邦证券法的定义，包括拟议公开发行的预期关闭日期以及公司对拟议公开发行收益的预期使用，以及 TERN-701 的潜在临床特征和相对优势。除历史事实声明外，本新闻稿中包含的所有声明均为前瞻性声明。在某些情况下，您可以通过诸如 “目标”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“设计”、“由于”、“估计”、“期待”、“目标”、“打算”、“可能”、“目标”、“计划”、“定位”、“潜在”、“预测”、“寻求”、“应该”、“目标”、“将”、“会” 等术语或其他类似表达来识别前瞻性声明，这些术语是对未来事件和未来趋势的预测或指示，或这些术语的否定形式或其他可比术语。公司在很大程度上基于其当前的预期、估计、预测和关于未来事件及财务趋势的预测来制定这些前瞻性声明，这些事件和趋势可能会影响其财务状况、经营结果、商业战略和财务需求。鉴于这些前瞻性声明中存在的重大不确定性，您不应将前瞻性声明视为未来事件的预测。这些声明受到风险和不确定性的影响，这可能导致实际结果和公司计划的实施发生重大变化，包括与公司当前和未来的研究与开发活动、临床前研究和临床试验的启动、成本、时间、进展、结果和效用相关的风险。这些风险并不详尽。有关可能影响公司和发行的风险因素的详细讨论，请参阅公司在 SEC 报告中识别的风险因素，包括但不限于截至 2024 年 12 月 31 日的年度报告（Form 10-K）、后续的季度报告（Form 10-Q）以及其初步招股说明书补充。除法律要求外，公司没有义务因任何原因公开更新任何前瞻性声明。</p>
<p><strong>Terns 联系方式</strong></p>
<p><strong>投资者</strong></p>
<p>Justin Ng</p>
<p>investors@ternspharma.com</p>
<p><strong>媒体</strong></p>
<p>Jenna Urban</p>
<p>CG Life</p>
<p>media@ternspharma.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOaU0zTXpFMU1EVTFJekl5TURReE5qTT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOaU0zTXpFMU1EVTFJekl5TURReE5qTT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png"/></p>

TERN

<p>Terns Pharmaceuticals 宣布其增资的 6.5 亿美元公开发行定价为每股 40 美元，共计 16,250,000 股。此次发行预计将于 2025 年 12 月 11 日完成，Jefferies、TD Cowen 和 Leerink Partners 担任主承销商。募集资金将用于研究、临床试验以及 TERN-701 的开发等其他用途。公司已向美国证券交易委员会（SEC）提交了一个货架注册声明，发行将通过招股说明书补充文件进行</p>

<p>FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns.</p>
<div class="lb-trans"><p>加利福尼亚州福斯特城，2025 年 12 月 9 日（GLOBE NEWSWIRE）——Terns Pharmaceuticals, Inc.（“Terns” 或 “公司”）（纳斯达克：TERN），一家临床阶段的肿瘤学公司，今天宣布其增大规模的承销公开发行价格为每股 40.00 美元的 16,250,000 股普通股，未扣除承销折扣和佣金。此次发行的总收益预计为 6.5 亿美元，未扣除承销折扣和佣金及 Terns 需支付的其他发行费用，且不包括承销商购买额外股份的选择权。Terns 已授予承销商一个 30 天的选择权，以每股公开发行价格购买最多 2,437,500 股普通股，扣除承销折扣和佣金。此次发行预计将于 2025 年 12 月 11 日完成，需满足惯常的交割条件。所有证券均由 Terns 提供。</p>
</div><p>Jefferies, TD Cowen and Leerink Partners are acting as lead book-running managers for the proposed offering. Mizuho, Citizens Capital Markets and Oppenheimer &amp; Co. are also acting as co-managers for the proposed offering.</p>
<div class="lb-trans"><p>Jefferies、TD Cowen 和 Leerink Partners 担任此次发行的主要账簿管理人。Mizuho、Citizens Capital Markets 和 Oppenheimer &amp; Co.也担任此次发行的共同管理人。</p>
</div><p>Terns intends to use the net proceeds from the proposed offering to fund research, clinical trials, development and manufacturing of key product candidates, including TERN-701, initial activities in preparation for the potential future commercial launch of TERN-701 and for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Terns 计划将此次发行的净收益用于资助研究、临床试验、关键产品候选者的开发和生产，包括 TERN-701，准备 TERN-701 潜在未来商业发布的初步活动，以及用于营运资金和一般企业用途。</p>
</div><p>A shelf registration statement on Form S-3 (File No. 333-292016) relating to the securities offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on December 9, 2025 and automatically became effective on such date. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the preliminary prospectus supplement, final prospectus supplement, and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com, TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com, or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ex. 6105, or by email at syndicate@leerink.com.</p>
<div class="lb-trans"><p>关于此次公开发行的证券，已于 2025 年 12 月 9 日向证券交易委员会（“SEC”）提交了 S-3 表格的注册声明（文件编号 333-292016），并于该日期自动生效。此次发行仅通过补充招股说明书和构成注册声明一部分的招股说明书进行。与此次发行相关的初步补充招股说明书和招股说明书已提交给 SEC，并可在 SEC 网站 www.sec.gov 上获取。与此次发行相关的最终补充招股说明书将提交给 SEC。初步补充招股说明书、最终补充招股说明书及与此次发行相关的招股说明书的副本在可用时可从 Jefferies LLC 索取，注意：股权承销招股说明书部门，地址：520 Madison Avenue, New York, NY 10022，电话：877-821-7388，或通过电子邮件联系 prospectus_department@jefferies.com，TD Securities (USA) LLC，c/o Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，或通过电子邮件联系 TDManualrequest@broadridge.com，或 Leerink Partners LLC，注意：承销部门，地址：53 State Street, 40th Floor, Boston, MA 02109，电话：1-800-808-7525 ex. 6105，或通过电子邮件联系 syndicate@leerink.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他管辖区内进行这些证券的出售，若在该州或其他管辖区内的证券法规定之前进行注册或资格审查，则该出售将是非法的。</p>
</div><p><strong>About Terns Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Terns Pharmaceuticals</strong></p>
</div><p>Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals 是一家临床阶段的肿瘤学公司，重新构想已知生物学，以提供高影响力的药物。我们的主导项目 TERN-701 是一种高度选择性的别构 BCR-ABL 抑制剂，具有潜在的最佳疾病特征，可能在慢性髓性白血病（CML）现有治疗的疗效、安全性和便利性方面显著改善。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including the anticipated closing date of the proposed public offering and the Company’s anticipated use of proceeds of the proposed public offering and the potential clinical profile and relative benefits of TERN-701. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and its preliminary prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</p>
<div class="lb-trans"><p>本新闻稿包含关于 Terns Pharmaceuticals, Inc.（“公司”、“我们” 或 “我们的”）的前瞻性声明，符合联邦证券法的定义，包括拟议公开发行的预期关闭日期以及公司对拟议公开发行收益的预期使用，以及 TERN-701 的潜在临床特征和相对优势。除历史事实声明外，本新闻稿中包含的所有声明均为前瞻性声明。在某些情况下，您可以通过诸如 “目标”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“设计”、“由于”、“估计”、“期待”、“目标”、“打算”、“可能”、“目标”、“计划”、“定位”、“潜在”、“预测”、“寻求”、“应该”、“目标”、“将”、“会” 等术语或其他类似表达来识别前瞻性声明，这些术语是对未来事件和未来趋势的预测或指示，或这些术语的否定形式或其他可比术语。公司在很大程度上基于其当前的预期、估计、预测和关于未来事件及财务趋势的预测来制定这些前瞻性声明，这些事件和趋势可能会影响其财务状况、经营结果、商业战略和财务需求。鉴于这些前瞻性声明中存在的重大不确定性，您不应将前瞻性声明视为未来事件的预测。这些声明受到风险和不确定性的影响，这可能导致实际结果和公司计划的实施发生重大变化，包括与公司当前和未来的研究与开发活动、临床前研究和临床试验的启动、成本、时间、进展、结果和效用相关的风险。这些风险并不详尽。有关可能影响公司和发行的风险因素的详细讨论，请参阅公司在 SEC 报告中识别的风险因素，包括但不限于截至 2024 年 12 月 31 日的年度报告（Form 10-K）、后续的季度报告（Form 10-Q）以及其初步招股说明书补充。除法律要求外，公司没有义务因任何原因公开更新任何前瞻性声明。</p>
</div><p><strong>Contacts for Terns</strong></p>
<div class="lb-trans"><p><strong>Terns 联系方式</strong></p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Justin Ng</p>
<div class="lb-trans"><p>Justin Ng</p>
</div><p>investors@ternspharma.com</p>
<div class="lb-trans"><p>investors@ternspharma.com</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒体</strong></p>
</div><p>Jenna Urban</p>
<div class="lb-trans"><p>Jenna Urban</p>
</div><p>CG Life</p>
<div class="lb-trans"><p>CG Life</p>
</div><p>media@ternspharma.com</p>
<div class="lb-trans"><p>media@ternspharma.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOaU0zTXpFMU1EVTFJekl5TURReE5qTT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg3NiM3MzE1MDU1IzIyMDQxNjM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png"/></p>

Terns 宣布其扩大至 6.5 亿美元的公开发行定价 | TERN 股票新闻